13314-69-7

Basic information

• Product Name: 1-Benzyl-4-(4-methoxyphenyl)tetrahydropyridine
• Synonyms: 1-BENZYL-4-(4-METHOXYPHENYL)TETRAHYDROPYRIDINE
• CAS NO: 13314-69-7
• Molecular Formula: C₁₉H₂₁NO
• Molecular Weight: 279.38
• Mol File: 13314-69-7.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Benzyl-4-(4-methoxyphenyl)tetrahydropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Benzyl-4-(4-methoxyphenyl)tetrahydropyridine(13314-69-7)
• EPA Substance Registry System: 1-Benzyl-4-(4-methoxyphenyl)tetrahydropyridine(13314-69-7)

Safety Data

• Hazardous Substances Data: 13314-69-7(Hazardous Substances Data)

Usage

Description

1-Benzyl-4-(4-methoxyphenyl)tetrahydropyridine, commonly known as MPTP, is a synthetic compound that closely resembles the neurotransmitter dopamine in structure. It functions as a potent neurotoxin, primarily recognized for its ability to induce neurodegenerative conditions that mimic Parkinson's disease. MPTP is known to selectively destroy dopaminergic neurons in the brain, resulting in Parkinson's-like symptoms such as tremors, rigidity, and bradykinesia.

Uses

Used in Scientific Research:
1-Benzyl-4-(4-methoxyphenyl)tetrahydropyridine is used as a neurotoxin in scientific research for inducing Parkinson's-like symptoms in animal models. This application is crucial for studying the pathophysiology of Parkinson's disease and for evaluating potential treatments and therapies aimed at alleviating or reversing the disease's progression.
Used in Forensic Toxicology:
MPTP is also utilized in forensic toxicology to investigate its potential role in causing parkinsonism in individuals who have used recreational drugs. Understanding the toxic effects of MPTP in such cases can aid in the development of preventive measures and interventions for drug users at risk of developing Parkinson's-like symptoms.

Upstream product

• 104-92-7 1-bromo-4-methoxy-benzene 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 623-12-1 4-chloromethoxybenzene 
• 50-00-0 formaldehyd 
• 5720-07-0 4-methoxyphenylboronic acid 
• 70882-08-5 N-benzylbuta-2,3-dien-1-amine 
• 107301-61-1 N-benzyl-4-amino-1-butyne 
• 6717-00-6 1-benzyl-4-(4-methoxy-phenyl)-piperidin-4-ol 
• 7732-18-5 water 
• 936231-01-5 1-benzyl-4-(benzyldimethylsilanyl)-1,2,3,6-tetrahydro-pyridine hydrochloride 
• 696-62-8 para-iodoanisole 
• 13139-86-1 4-methoxyphenyl magnesium bromide 

Downstream Products

• 188866-44-6 (±)-(3,4-trans)-4-(4-hydroxyphenyl)piperidin-3-ol 
• 188874-90-0 (3R,4S,5S)-4-(4-Hydroxy-phenyl)-piperidine-3,5-diol 
• 188874-86-4 RS)-1-benzyl-4-(4-methoxy-phenyl)-1,2,3,6-tetrahydro-pyridin-3-ol 
• 188874-87-5 (RS)-1-benzyl-3-ethoxy-4-(4-methoxy-phenyl)-1,2,3,6-tetrahydro-pyridine 
• 188874-91-1 (3R,4S,5S)-3,5-Dihydroxy-4-(4-hydroxy-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 188874-42-2 (3R,4S,5S)-4-[4-(3-Benzyloxy-propoxy)-phenyl]-3,5-dihydroxy-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Substituted piperidines - Highly potent renin inhibitors due to induced fit adaptation of tile active site

The identification, synthesis and activity of a novel class of piperidine renin inhibitors is presented. The most active compounds show activities in the picomolar range and are among the most potent renin inhibitors ever identified.

BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder

There is a significant unmet medical need for more efficacious and rapidly acting antidepressants. Toward this end, negative allosteric modulators of the N-methyl-d-aspartate receptor subtype GluN2B have demonstrated encouraging therapeutic potential. We

Synthesis and SAR study of 4-arylpiperidines and 4-aryl-1,2,3,6- tetrahydropyridines as 5-HT2C agonists

A series of substituted 4-arylpiperidines and a smaller family of 4-aryl-1,2,3,6-tetrahydropyridines were synthesized and their biological activity at the 5-HT2C receptor studied to determine whether either series showed noteworthy agonist activity. Structure-activity relationships were developed from the performed receptor binding assays and functional studies, and the results of the analysis are presented herein.